Ann: Positive final DEP irinotecan Phase 2 clinical trial results, page-12

Yes thrasher suggest you listen to the webinar where Cheryl stated that big pharma are not interested in our three dep drugs at the Ph2 completion level. They are more interested in more current and emerging treatments. The inference was that if Ph3 trials were completed then potentially they would take a look.

If our mob hadn’t stuffed around for literally years with these trials it may have resulted in some serious deals.
This country centric or region centric approach they are mentioning seems very strange to me particularly in relation to approvals. I think we deserve a lot more
detail about this approach as it all sounds wishy washy to me